Navigation Links
ATL/TV1102 Trial Results Presented at World Congress on Treatment and Research in Multiple Sclerosis
Date:9/21/2008

expected to grow with the introduction of novel treatment options. There remains a high demand for more effective and better tolerated treatments.

About ATL/TV1102 for MS: ATL/TV1102 is an antisense drug discovered by Isis Pharmaceuticals, Inc. and licensed to ANP. Antisense drugs specifically block disease-causing proteins from being produced by interacting with their intended target based on information in the genetic code. ATL/TV1102 is a second-generation antisense inhibitor of CD49d, a subunit of VLA-4 (Very Late Antigen-4). In inflammation, white blood cells (leukocytes) move out of the bloodstream into the inflamed tissue, for example, the CNS in MS, and the lung airways in asthma. The inhibition of VLA-4 may prevent white blood cells from entering sites of inflammation, thereby halting progression of the disease. VLA-4 is a clinically validated target in the treatment of MS. Antisense inhibition of VLA-4 has demonstrated positive effects in a number of animal models of inflammatory disease including MS (Myers et al. J Neuroimmunol 160, p12-24, 2005).

About Antisense Therapeutics Limited: Antisense Therapeutics Limited (ASX: ANP) is an Australian publicly listed biopharmaceutical drug discovery and development company. Its mission is to create, develop and commercialize antisense pharmaceuticals for large unmet markets. ANP has two drugs in development and two drugs in pre-clinical research. ATL/TV1102 (injection) has completed a Phase IIa trial as a potential treatment of multiple sclerosis. ATL1103 is a second-generation antisense drug designed to lower blood IGF-I levels and is entering pre-clinical development as a potential treatment for acromegaly and vision disorders. ATL/TV1102 (inhaled) is at the pre-clinical research stage as a potential treatment for asthma. ATL1101 is a second-generation antisense drug at the pre-clinical research stage being investigated as a potential treatment for prostate cancer. ATL/TV1102 has been licensed to T
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.; Antisense Therapeutics Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... , Sept. 2, 2015  Neurocrine Biosciences, Inc. ... Coughlin , Chief Financial Officer of Neurocrine Biosciences, will ... New York City . ... at 11:25am ET (8:25am PT).  The presentation will be ... at http://www.neurocrine.com .   Listeners are ...
(Date:9/2/2015)... -- Research and Markets ( ... PharmaBiotech,s new report "Therapeutic Drug Monitoring - ... This report deals with therapeutic drug ... patient care by monitoring drug levels in the ... for improving outcome. TDM is viewed as a ...
(Date:9/2/2015)... Sept. 2, 2015  MiMedx Group, Inc. (NASDAQ: ... human amniotic tissue and patent-protected processes to develop ... Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic ... inaccurate statements published by the Musculoskeletal Transplant Foundation ... 2015. MTF,s September 1st press release ...
Breaking Medicine Technology:Global Therapeutic Drug Monitoring Technologies, Markets, and Companies Report 2015 - Updated 2015 Analysis with Forecasts to 2024 2MiMedx Corrects A Second Inaccurate MTF Press Release 2MiMedx Corrects A Second Inaccurate MTF Press Release 3
... Triage Wireless(TM), Inc., a medical device company developing a ... it has changed its corporate name to Sotera Wireless(TM), ... Company,s name arose from a settlement with Inverness Medical ... Triage brand. Inverness obtained the Triage brand when ...
... , RARITAN, N.J., Nov. 16 ... and in 70 percent of new cases, no cause is apparent. ... knowing when the next seizure will occur, how long it will ... of emotions as they cope with the condition. The wonder ...
Cached Medicine Technology:National Expressions of Courage Art Contest Unveils Stories of Inspiration 2National Expressions of Courage Art Contest Unveils Stories of Inspiration 3National Expressions of Courage Art Contest Unveils Stories of Inspiration 4National Expressions of Courage Art Contest Unveils Stories of Inspiration 5
(Date:9/2/2015)... ... ... Good health and a good cause paired up at The Barclays this ... $11,000 to the New Jersey Golf Foundation through its Healthy Steps Challenge. After ... Horizon BCBSNJ challenged PGA TOUR golfer and NJ native Morgan Hoffmann to add more ...
(Date:9/2/2015)... ... 02, 2015 , ... The Hydration Room, Orange County’s first ... second location this week at 31542 S. Coast Hwy, Suite #4, Laguna Beach, ... for patients to relax while receiving safe and effective therapies. Also offering complimentary ...
(Date:9/2/2015)... WI (PRWEB) , ... September 02, 2015 , ... ... Cypress Benefit Administrators is taking action after seeing a significant increase ... TPA’s Argus Claim Review division has found many cases of OON ASCs encouraging ...
(Date:9/2/2015)... , ... September 02, 2015 , ... Amada Senior Care, ... office in Kansas – its Johnson County location. Amada franchise partners Mike ... has a registered nurse background and spent over 20 years in medical device sales ...
(Date:9/2/2015)... Fredericksburg, VA (PRWEB) , ... September 02, 2015 ... ... integrator of document imaging, content, records and case management solutions and services to ... of PurePAGE®, its Image Re-sizing and Image Clean-up utility for IBM’s Datacap document ...
Breaking Medicine News(10 mins):Health News:Horizon BCBSNJ’s Healthy Steps Challenge Raises an Additional $6,000 for the NJ Golf Foundation with Help from PGA TOUR Golfer Morgan Hoffmann 2Health News:Horizon BCBSNJ’s Healthy Steps Challenge Raises an Additional $6,000 for the NJ Golf Foundation with Help from PGA TOUR Golfer Morgan Hoffmann 3Health News:The Hydration Room Opens New Location In Laguna Beach, California 2Health News:The Hydration Room Opens New Location In Laguna Beach, California 3Health News:The Hydration Room Opens New Location In Laguna Beach, California 4Health News:TPA Cracks Down on Forbidden Tactics Used by Out-of-Network Surgical Centers 2Health News:TPA Cracks Down on Forbidden Tactics Used by Out-of-Network Surgical Centers 3Health News:Amada Senior Care Expands to Greater Kansas City 2Health News:EDAC Systems, Inc. announces a new version of its Image Enhancement and Image Re-Sizing utility EDAC’s PurePAGE® 2Health News:EDAC Systems, Inc. announces a new version of its Image Enhancement and Image Re-Sizing utility EDAC’s PurePAGE® 3
... Wash. , Feb. 4 The Carol Milgard Breast ... and Drug Administration (FDA) for adhering to the most rigorous quality ... (MQSA).  Receiving the "All Items in Compliance" rating from the FDA ... not received this high quality standard.   , John Peixotto ...
... PALM BEACH, Fla. , Feb. 4 The American ... suffer from some type of cardiovascular disease. Many of those people ... event like the Super Bowl or World Cup where the tension ... rates from heart attacks in 2002 and 2001, doctors in ...
... cancer is the second leading cause of cancer-related deaths in ... of screening for this disease, rates of screening for colorectal ... cancer, particularly breast and cervical. Although the screening rates in ... from 20-30 percent in 1997 to nearly 55 percent in ...
... for athletes to cheat, researchers say , THURSDAY, Feb. 4 ... scientists are warning of a new breed of performance-enhancing agents ... to detect. , , Some researchers are already ... how they can modify genes to boost endurance or muscle ...
... , GAINESVILLE, Fla. , Feb. 4 ... announce today that they have jointly selected Sg2 , a healthcare ... children,s hospital. The assessment began in January with findings projected to be ... at Sg2 will handle this very important assessment, delivering the ...
... , , , ... /PRNewswire-Asia-FirstCall/ -- Huifeng Bio-,Pharmaceutical Technology, Inc. (OTC Bulletin Board: HFGB), ... materials for,use in pharmaceutical, nutraceutical and food production, today announced,preliminary ... Huifeng Bio-Pharmaceutical Technology anticipates revenues between $13,million ...
Cached Medicine News:Health News:Carol Milgard Breast Center Awarded Highest Government Rating for Mammography Sites 2Health News:Top 10 Ways to Avoid a Heart Attack This Super Bowl 2Health News:Top 10 Ways to Avoid a Heart Attack This Super Bowl 3Health News:Panel calls for reducing colorectal cancer deaths by striking down barriers to screening 2Health News:'Gene Doping' May Be Next Wave of Sports Tampering 2Health News:'Gene Doping' May Be Next Wave of Sports Tampering 3Health News:Sebastian Ferrero Foundation and Shands HealthCare Have Selected Sg2 to Conduct a Needs Assessment for a Gainesville-Based Children's Hospital 2Health News:Sebastian Ferrero Foundation and Shands HealthCare Have Selected Sg2 to Conduct a Needs Assessment for a Gainesville-Based Children's Hospital 3Health News:Huifeng Bio-Pharmaceutical Provides Preliminary 2009 Financial Results and 2010 Guidance 2Health News:Huifeng Bio-Pharmaceutical Provides Preliminary 2009 Financial Results and 2010 Guidance 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: